Hematopoietic cell transplantation (HCT) after low-dose, total body irradiation-based regimen increased leukemia-free survival (LFS) in elderly patients with cytogenetic high-risk AML compared to ...

Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial. Discrepancy of blast percentage between the bone marrow ...

The study included 82 participants who have been on long-term tyrosine-kinase inhibitor treatment for chronic myeloid leukemia; 32 participants were treated with dasatinib and 50 were treated with ...

Most of the complete hematologic responses occurred at doses of dasatinib of 50 mg per day or more, whereas most cytogenetic responses required higher doses (Table 8 of the Supplementary Appendix).

and viability in the dasatinib insensitive MCF7 cell line, lowering the IC 50 of doxorubicin by more than one log unit. Additionally, combination treatment of dasatinib-sensitive MDA-MB-231 cells ...

After treatment with cetuximab (500 nM), dasatinib (50 nM) and their combination, cell lysates were incubated with the membrane. Thereafter, a cocktail of biotinylated detection antibodies, ...

DASATINIB-TEVA contains the active ingredient ... The usual starting dose is 100 mg once daily (either as one 100 mg tablet or two 50 mg tablets). The entire dose of 100 mg is to be taken at ...

to manufacture and market Dasatinib Tablets in 20 mg, 50 mg, 70 mg, 80 mg, 100 mg and 140 mg strengths. These products are bioequivalent and therapeutically equivalent to Sprycel Tablets by ...

Dasatinib was withheld again. After resolution of the second episode, dasatinib was reintroduced together with 50 mg of prednisone per day; no recurrence of panniculitis was noted, even when the ...

to market Dasatinib tablets in multiple strengths—20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. "Zydus has received final approval from the USFDA to manufacture Dasatinib tablets in various ...